Business, energy, technology, markets and global industry news from Business News Today

University of Leicester

PharmaDeviceNews University of Leicester
Representative image of asthma and atopic dermatitis research as Aclaris Therapeutics’ investigational antibody ATI-052 demonstrates promising Phase 1b clinical results, reducing airway inflammation by 59% and improving eczema severity by 58%.
Pharma & Biotech

Could ATI-052 offer a new approach to asthma and eczema? Phase 1b findings support further testing

Aclaris Therapeutics' ATI-052 shows promising Phase 1b asthma and eczema results. Explore the clinical findings and upcoming Phase 2b plans.

Read More